Thrombectomy Devices Market to Make Great Impact in Near Future by 2026 | Applied Medical, Argon Medical Devices, Inc., Boston Scientific Corporation, BTG International, Capture Vascular, Claret Medical, Control Medical Technology

Manufacturers are focused on gaining maximum product approval and innovating existing products in order to gain market share. In May 2018, Stryker Corporation received an expanded CE Mark approval in the European Union for its Trevo thrombectomy device as a front-line treatment for acute ischemic stroke patients.

In August 2018, NexGen Medical Systems, Inc., completed the first human use of their XCOIL Large Vessel (18mm) Thrombectomy System for the treatment of deep vein thrombosis (DVT). The new device, an expansion of the successful XCOIL 12mm System, is designed to rapidly remove blood clots in large vessels, such as the iliac vein. In May 2017, SurModics acquired Embolitech’s thrombectomy platform and the associated intellectual property in a deal worth US$ 5 million, with additional payments based on regulatory milestones.

Download PDF Brochure @ www.coherentmarketinsights.com/insight/request-pdf/2254

Market Dynamics

Increasing incidences of deep vein thrombosis (DVT), pulmonary embolism (PE), and stroke are the major factors fuelling high demand for thrombectomy devices. Pulmonary embolism (PE) is the most serious and life-threating complication caused due to thromboembolism. Inappropriate treatment of acute DVT can result in thrombus organization and post-thrombosis syndrome (PTS) in patients, seriously affecting their quality of life. According to University of California, about 10-15% of stroke patients are candidates for thrombectomy, and about 4.7% of patients underwent the treatment in 2015, up from 1.5% in 2009.

Despite high demand and applicability of thrombectomy devices, it also poses certain limitations, which can restrain growth of the market during the forecast period. For instance, side effects of thrombectomy include intracerebral hemorrhage, subarachnoid hemorrhage, device related injury to the vessel wall, and fragmentation of the target thrombus.

High cost of thrombectomy devices eventually increases its procedure cost, which is a major setback for surgery adoption. According to NICE, July 2018 data, the cost of mechanical thrombectomy devices ranges between US$ 700 to US$ 1,719 for aspiration catheters and US$ 1,911 to US$ 6,372 for stent retrievers per unit excluding taxes. Furthermore, other side effects of thrombectomy devices include bleeding from the area where the catheter is inserted, and appearance of bruise in the area causing pain. Moreover, with the breakdown of blood clots, chemicals are released, which can temporarily affect kidney function or rarely the heart.

Thrombectomy Devices Market - Competitive Landscape

Key players operating in the global thrombectomy devices market include Applied Medical, Argon Medical Devices, Inc., Boston Scientific Corporation, BTG International, Capture Vascular, Claret Medical, Control Medical Technology, Edwards Lifesciences Corporation, Johnson & Johnson, Medtronic PLC, Merit Medical Systems, Inc., Minnetronix, Inc., Nexgen Medical Systems, Inc., Natec Medical Ltd., Penumbra, Inc., Phenox GmbH, Stentys SA, Spectranetics Corporation, Straub Medical AG, Stryker Corporation, Terumo Corporation, and Teleflex Incorporated.

Get Exclusive Sample Copy @ www.coherentmarketinsights.com/insight/request-sample/2254

Detailed Segmentation:

Global Thrombectomy Devices Market, By Product Type:
Mechanical Thrombectomy Devices
Aspiration Thrombectomy Devices
Hydrodynamic Thrombectomy Devices
Ultrasonic Thrombectomy Devices
Global Thrombectomy Devices Market, By Application:
Neurovascular
Cardiovascular
Peripheral Vascular
Global Thrombectomy Devices Market, By End User:
Hospitals
Ambulatory Surgical Centers
Research Laboratories and Academic Institutes

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

1001 4th Ave,, #3200, Seattle, WA 98154

This release was published on openPR.